1 / 16

Schackman BR , Metsch LR, Colfax GN, Leff JA, Wong A,

The cost-effectiveness of on-site rapid HIV testing in substance abuse treatment: results of the CTN 0032 randomized trial. Schackman BR , Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes LF, Paltiel AD, Walensky RP.

jody
Télécharger la présentation

Schackman BR , Metsch LR, Colfax GN, Leff JA, Wong A,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The cost-effectiveness of on-site rapid HIV testing in substance abuse treatment: results of the CTN 0032 randomized trial Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes LF, Paltiel AD, WalenskyRP 6th IAS Conference on HIV Pathogenesis, Treatment, and Prevention July 18, 2011

  2. US National HIV/AIDS Strategy • Target: increase proportion of people living with HIV who know their status from 79% to 90% by 2015 • Implementation: Federally-funded substance abuse and mental health treatment clinics to offer voluntary, routine HIV testing

  3. HIV testing in substance abuse treatment centers • Less than one-third of US drug treatment programs offer HIV testing and counseling • Less than one-half of community treatment programs in the National Drug Abuse Clinical Trials Network (CTN) make HIV testing available, either in the program or through referral

  4. Objective • To project the life expectancy gains, costs and cost-effectiveness of 3 HIV testing strategies in substance abuse treatment centers evaluated in the CTN Rapid Testing and Counseling Study randomized controlled trial (CTN 0032)

  5. Analytic overview • We used data on short-term outcomes from CTN 0032 (Abstract TUPE402) • To project long-term clinical and economic outcomes, we used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model, a computer simulation state-transition model of HIV disease natural history, detection and treatment

  6. Model outcomes • For HIV-infected individuals: • Life expectancy, undiscounted • Quality-adjusted life years (QALYs) gained and cost of additional care due to early detection, discounted at 3% annually • For HIV-uninfected individuals: • Cost of HIV testing offer • All costs are in 2009 US dollars

  7. Cost-effectiveness is about value for money • Incremental cost-effectiveness ratio: • US cost-effectiveness threshold: <$100,000/QALY

  8. Strategies examined • No HIV testing • Offer of referral to off-site HIV testing only • Offer of on-site rapid HIV testing with verbal information about testing only • Offer of on-site rapid HIV testing with risk reduction counseling

  9. Cohort description *estimated

  10. Input parameters by strategy

  11. Base case cost-effectiveness results

  12. Sensitivity analysis: cost-effectiveness of on-site testing + information vs. no intervention

  13. Limitations • Assume HIV+ individuals who receive test results will be linked to care, and consistently receive guideline-concordant care • Potential benefit of reduced HIV transmission due to earlier detection is not included • Additional start-up costs will be required to implement on-site HIV testing

  14. Conclusions • In substance abuse treatment centers: • Referral for off-site testing is less costly but also less efficient than on-site testing • On-site risk reduction counseling adds cost without either reducing sexual risk behavior or increasing acceptance of HIV testing, and is not cost-effective • Offering rapid HIV testing on-site in substance abuse treatment programs is cost-effective using the current US threshold of <$100,000/QALY

  15. Funding • National Drug Abuse Treatment Clinical Trials Network (CTN): U10 DA013720, U10DA13720-09S, U10 DA020036, U10DA15815, U10DA13034, U10DA013038, U10 DA013732, U10 DA13036, U10 DA13727, U10DA015833, HHSN271200522081C, HHSN271200522071C • National Institute on Drug Abuse: R01 DA027379, K23 DA019809 • National Institute of Mental Health: R01 MH063869 • National Institute of Allergy and Infectious Diseases: R37 A1042006

  16. Special thanks to site coordinators, staff, and participants CPCDS: Antoine Douiah, Dorothy Sandstrom, Carrie Baron-Myak La Frontera: Pat Penn, Roger Owen, and Sue McDavitt Daymark: Robert Werstlein, Jessica Sides Chesterfield: Dace Svikas, Ned Snead, Laurie Safford Glenwood: Robert Schwartz, Lil Donnard, Lynn Calvin MCCA: Steve Martino, David Avila, Stacy Botex Wheeler: Steve Martino, Ray Muszynksi, Brandi Welles CODA: Todd Korthuis, Katharina Weist, Diane Lape Lifelink: Sarah Erickson, Michael DeBernardi, Meredith Davis LRADAC: Louise Haynes, Beverly Holmes Morris Village: Louise Haynes, Kim Pressley Gibson: Angela Case-Williams, Kevin Steward, Andrew Johnson

More Related